United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$316.89 USD
+2.33 (0.74%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $316.92 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
United Therapeutics (UTHR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$302.00 | $400.00 | $240.00 | -3.99% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for United Therapeutics comes to $302.00. The forecasts range from a low of $240.00 to a high of $400.00. The average price target represents a decline of 4.75% from the last closing price of $317.05.
Analyst Price Targets (11)
Broker Rating
United Therapeutics currently has an average brokerage recommendation (ABR) of 1.54 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on 14 recommendations.
Of the 13 recommendations deriving the current ABR, 10 are Strong Buy, representing 76.92% of all recommendations. A month ago, Strong Buy represented 78.57%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/UTHR.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 11 | 11 | 11 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.54 | 1.54 | 1.50 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/27/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/12/2024 | Wells Fargo Securities | Tiago Fauth | Strong Buy | Strong Buy |
5/3/2024 | Goldman Sachs | Chris Shibutani | Hold | Hold |
5/2/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Joseph Thome | Strong Buy | Strong Buy |
3/15/2024 | Argus Research Corp. | Jasper Hellweg | Strong Buy | Strong Buy |
2/23/2024 | UBS | Ashwani Verma | Strong Buy | Strong Buy |
2/5/2024 | SVB Securities | Roanna Ruiz | Not Available | Strong Buy |
11/2/2023 | LadenburgThalmann | Matthew L Kaplan | Strong Buy | Strong Buy |
11/1/2023 | BTIG | Julian Harrison | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.54 |
ABR (Last week) | 1.54 |
# of Recs in ABR | 13 |
Average Target Price | $302.00 |
LT Growth Rate | 9.20% |
Industry | Medical - Drugs |
Industry Rank by ABR | 98 of 252 |
Current Quarter EPS Est: | 6.18 |